Outlook Therapeutics Management
Management criteria checks 2/4
Outlook Therapeutics' CEO is Russ Trenary, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is $1.76M, comprised of 34.1% salary and 65.9% bonuses, including company stock and options. directly owns 0.7% of the company’s shares, worth €1.20M. The average tenure of the management team and the board of directors is 2.5 years and 4.8 years respectively.
Key information
Russ Trenary
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 34.1% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$51m |
| Sep 30 2023 | US$2m | US$600k | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$60m |
| Mar 31 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | n/a | n/a | -US$70m |
| Sep 30 2022 | US$1m | US$600k | -US$66m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$60m |
| Dec 31 2021 | n/a | n/a | -US$53m |
| Sep 30 2021 | US$8m | US$145k | -US$53m |
Compensation vs Market: Russ's total compensation ($USD1.76M) is above average for companies of similar size in the German market ($USD702.03K).
Compensation vs Earnings: Russ's compensation has increased whilst the company is unprofitable.
CEO
Russ Trenary (65 yo)
2.8yrs
Tenure
US$1,758,862
Compensation
Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Executive Chairman | 6yrs | US$242.50k | 0.0027% € 4.5k | |
| President | 2.8yrs | US$1.76m | 0.70% € 1.2m | |
| Executive VP | 8.6yrs | no data | 0.0042% € 7.3k | |
| Chief Commercial Officer | 5.4yrs | US$718.20k | 0.18% € 310.1k | |
| Senior Vice President | 2.1yrs | no data | no data | |
| Senior Vice President of Licensing and M&A | 2.2yrs | no data | no data | |
| Senior Vice President of Medical Affairs | 1.3yrs | no data | no data | |
| Senior Vice President of Clinical Development & Regulatory Affairs | no data | no data | no data | |
| Senior VP - Head of Europe | less than a year | no data | no data |
2.5yrs
Average Tenure
61yo
Average Age
Experienced Management: 41ON's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Executive Chairman | 6yrs | US$242.50k | 0.0027% € 4.5k | |
| President | 2.8yrs | US$1.76m | 0.70% € 1.2m | |
| Executive VP | 5.7yrs | no data | 0.0042% € 7.3k | |
| Independent Director | 8.3yrs | US$95.00k | 0.11% € 181.5k | |
| Independent Director | 1.7yrs | US$79.00k | 0% € 0 | |
| Independent Non-Employee Director | 4yrs | US$112.50k | 0% € 0 | |
| Board Observer | no data | no data | no data | |
| Independent Non-Employee Director | 4yrs | US$79.00k | 0% € 0 | |
| Independent Director | 6.6yrs | US$113.00k | 0.015% € 26.1k | |
| Independent Director | 6.5yrs | US$110.00k | 0.023% € 38.7k | |
| Independent Director | 3.8yrs | US$75.00k | 0% € 0 |
4.8yrs
Average Tenure
62yo
Average Age
Experienced Board: 41ON's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/22 01:08 |
| End of Day Share Price | 2024/01/24 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Outlook Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |